Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Non Interventional (NI) Open Label Prospective Study On Liprimar (Atorvastatin) In Patients With Coronary Heart Disease (CHD) And High Risk Of Cardiovascular Complications

NCT00993915 is registered in ClinicalTrials.gov with Pfizer's Upjohn has merged with Mylan to form Viatris Inc. as lead sponsor.

NCT NCT00993915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00993915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Non Interventional (NI) Open Label Prospective Study On Liprimar (Atorvastatin) In Patients With Coronary Heart Disease (CHD) And High Risk Of Cardiovascular Complications
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase
Observational
Overall status
Completed
Start date
April 30, 2010
Completion date
December 31, 2011
Enrollment
687 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular diseases, coronary artery disease